Castle Biosciences
360Dx Top 30 Drops 9 Percent in February
Of the 30 companies on the list, 22 firms saw their share prices decline month over month, while eight companies saw their stock prices rise.
Castle Biosciences Q4 Revenues up 31 Percent
The company saw a boost in testing volume in the fourth quarter, but not across all its assays, while full-year revenues grew 51 percent.
Preliminary Earnings Roundup: Hologic, Exact Sciences, QuidelOrtho, Guardant Health, More
Numerous firms reported preliminary revenues along with other business updates on Sunday and Monday ahead of the annual JP Morgan Healthcare Conference.
CMS Contractors Novitas, FCSO Finalize Non-Coverage Decisions for Certain Cancer Genetic Tests
Tests from Castle Biosciences, Pacific Edge Diagnostics, Interpace Biosciences, Clinical Genomics, and the University of Pittsburgh Medical Center will no longer be covered.
New York State DOH Approves Castle Biosciences' Barrett’s Esophagus Test
The TissueCypher assay is designed to identify patients with Barrett's esophagus who are at risk of progressing to esophageal cancer.
Nov 5, 2024
Castle Biosciences Q3 Revenues up 39 Percent
Nov 1, 2024
360Dx Top 30 Falls 3 Percent in October
Sep 3, 2024
360Dx Top 30 Ticks up 2 Percent in August
Aug 5, 2024
Castle Biosciences Q2 Revenues Jump 74 Percent
Apr 1, 2024
360Dx Top 30 Rises 3 Percent in March
Mar 1, 2024
360Dx Top 30 Creeps up 1 Percent in February
Sep 1, 2023
360Dx Top 30 Ticks Down in August
Jul 5, 2023